mechanism of seizure initiation, which is assumed to start at a single, well-defined location. In contrast, the present recordings show that the seizure activity can involve the interaction between different local populations of neurons, but most of the time this does not generalize to larger cortical territories. Another interesting finding is that microseizures always precede the occurrence of full-blown seizures. Consequently, as these events are invisible from macroelectrode recordings, the localization of the epileptic focus, both in space and time, may be biased by this invisibility. However, whether the localization of such microseizure activity is critical to the localization of the focus at scales relevant to surgery remains to be demonstrated.
Why does one soldier, after sustaining a missile wound in the radial nerve on the battlefield, experience incapacitating neuropathic pain, while another, with a similar injury, complains of motor and sensory deficits in the absence of pain? Why is one patient with diabetic neuropathy disabled with neuropathic pain, while another patient with diabetic neuropathy of apparently similar severity experiences numbness or paraesthesias that are not painful? Pain is a complex phenomenon, mediated by transductive processes in the periphery, conduction to the spinal cord via first-order spinal sensory (dorsal root ganglion) neurons and processing at multiple higher levels that include the dorsal horn, thalamus and cortex. Multiple processes and molecules undoubtedly shape the perception of pain. Exciting progress, however, has recently been made in linking common variants of genes encoding two different ion channels within first-order sensory neurons along the pain pathway to inter-individual differences in pain. Discovery and characterization of these genetic variants, and of additional variants that will likely be identified in the future, open up the possibility of understanding more fully, at the molecular level, the processes that shape pain, and which may point the way to new therapeutic strategies.
Ion channels play major roles in electrical signalling along the pain pathway; their central role in this process is underscored by the preferential expression within dorsal root ganglion neurons of three sodium channels, Na v 1.7, Na v 1.8 and Na v 1.9, that are not expressed at high levels within the CNS . It is now well established that mutations of two ion channel genes can produce pain syndromes.
The Na v 1.7 sodium channel, which is preferentially expressed within dorsal root ganglion neurons including nocioceptors and sympathetic ganglion neurons (Djouhri et al., 2003) , displays slow inactivation in the closed-state near resting potential and amplifies small, subthreshold depolarizing stimuli (Herzog et al., 2003) . Gain-of-function mutations of SCN9A, the gene that encodes Na v 1.7, produce several syndromes characterized by severe pain. Na v 1.7 mutations that hyperpolarize activation voltage dependence produce inherited erythromelalgia, characterized by severe burning pain in the extremities, triggered by mild warmth (Dib-Hajj et al., 2005) . Another group of Na v 1.7 mutations, which impair inactivation and enhance persistent current, produce paroxysmal extreme pain disorder, characterized by episodes of severe perineal, periocular and perimandibular pain (Fertleman et al., 2006) . Loss-of-function mutations of Na v 1.7, on the other hand, produce channelopathy-associated insensitivity to pain (Cox et al., 2006) .
TRPA1 is a non-selective cation channel, also expressed within nocioceptive dorsal root ganglion neurons, that functions as a sensor of environmental irritants. Gain-of-function mutations of TRPA1 produce familial episodic pain syndrome, characterized by bouts of severe upper body pain, triggered by physical stress, cold or fasting (Kreymeyer et al., 2010) .
Inherited erythromelalgia, paroxysmal extreme pain disorder and familial episodic pain syndrome are caused by gain-of-function point mutations in ion channel genes and pain in these disorders can be considered to be 'channelopathic' (Waxman, 2010) . However, just as the borders between 'neuropathic' and 'inflammatory' pain can be blurred, so too can the boundaries of channelopathic pain be indistinct, since the genes encoding ion channels in the pain transcriptome may also contain polymorphisms or common variants that are present in control populations and do not cause disease per se, but modulate pain signalling, possibly via interactions with environmental or epigenetic factors.
In this issue of Brain, Costigan et al. (2010) provide compelling evidence linking a polymorphism in a potassium channel gene to chronic pain. Using gene profiling analysis to study global expression changes within rat dorsal root ganglion, they identify the KCNS1 potassium channel subunit gene as being expressed in dorsal root ganglion neurons, where its level of expression changes in three neuropathic pain models. KCNS1 encodes the K v 9.1 potassium channel subunit, which is widely expressed in the brain, but does not in itself display potassium channel activity. Rather, it modulates the level of expression and functional properties of other potassium channel (K v ) subunits (Salinas et al., 1997; Richardson and Kaczmarek, 2000) . Network analysis identifies KCNS1 as part of a group of neuronal signalling molecules related to sensory function, further supporting a role in pain. Single-nucleotide polymorphism analysis provides strong evidence linking a common amino acid changing allele within KCNS1 to increased pain in patients with spinal disc herniation, and with phantom limb pain and stump pain in patients with nerve injury due to traumatic limb amputation (Costigan et al., 2010) . Although functional implications of this polymorphism have not yet been determined, it is notable that potassium channel expression is dynamic, and that expression of several potassium channel subunits is down-regulated within dorsal root ganglion neurons following nerve injury (Ishikawa et al., 1999; Kim et al., 2002; Yang et al., 2004) . One approach for assessing functional effects of this polymorphism of K v 9.1 would be to transfect dorsal root ganglion neurons with the major or minor allele, and to examine the effects on potassium channel function by voltage clamp, or on dorsal root ganglion neuron firing properties by current clamp recording. It would not be surprising if this polymorphism was found to alter potassium channel function or expression within dorsal root ganglion neurons.
This demonstration of a common variant of a potassium channel subunit associated with pain extends recent work demonstrating that a common variant in a sodium channel can alter the excitability of dorsal root ganglion neurons and modulate pain sensitivity. Estacion et al. (2009) identified a non-synonymous amino acid changing single-nucleotide polymorphism within SCN9A, the gene encoding Na v 1.7, and showed that the minor allele depolarizes dorsal root ganglion neurons and increases (by 2-fold) their firing frequency in response to stimulation. The excitabilityincreasing allele is present in 31% of control Caucasian subjects (28% heterozygous for the minor allele; 3% homozygous), and would be expected to produce pain or a lower pain threshold . In association studies, Reimann et al. (2010) showed that the minor allele of this polymorphism is associated with a higher pain score in human subjects with sciatica, phantom pain following limb amputation and osteoarthritis. They also noted a trend toward increased sensitivity to multiple experimental stimuli, with evoked c-fibre-mediated heat pain reaching statistical significance, in an analysis of healthy females, free of pain at the time of examination, who were phenotyped with an array of noxious stimuli.
Approaching genomically based pain pharmacotherapeutics
It is also possible that common gene variants may modulate responsiveness to pain medications. Experienced clinicians are well aware that different patients respond to pain medications in different ways. Why does one patient with neuropathic pain due to a peripheral nerve lesion respond favourably to a drug such as carbamazepine, whereas another with a similar lesion does not? Why do some patients with painful diabetic neuropathy respond to certain pain medications, while others do not? One possibility is that single-nucleotide polymorphisms in genes controlling neuronal excitability within the pain-signalling pathway contribute to this variability in pharmacotherapeutic response. Studies on mutant Na v 1.7 sodium channels, identified in patients with inherited erythromelalgia, have revealed single amino acid substitutions that reduce, or enhance, blocking effects of agents such as lidocaine, mexiletine and carbamazepine Choi et al., 2009; Fischer et al., 2009) . It seems reasonable to suggest that there are polymorphisms that, while not producing disease, alter the responsiveness of various ion channels to pharmacotherapeutic agents. Identification and functional characterization of these single-nucleotide polymorphisms may permit identification of patients who are more likely to respond favourably to various pharmacotherapeutic interventions.
What next?
Now that mutations in two ion channel genes encoding Na v 1.7 and TRPA1 have been shown to produce pain syndromes, and common variants that appear to regulate pain sensitivity have been identified in two ion channels (Na v 1.7 and K v 9.1) within the pain transcriptome (Table 1) , what next? Interestingly, each of these channels has a major action within dorsal root ganglion neurons, which are first-order sensory neurons that project to the CNS. Multiple sodium channel isoforms are present within nocioceptive dorsal root ganglion neurons where they collaborate in the production of high-frequency firing , but pain-linked mutations have thus far not been found in the genes for any of these sodium channel isoforms other than Na v 1.7. Mutations that cause epilepsy have been found in Na v 1.3 (Holland et al., 2008) ; since this channel is up-regulated (Waxman et al., 1994) and contributes to hyperexcitablity in dorsal root ganglion neurons following nerve injury (Cummins and Waxman, 1997) , it would be interesting to determine whether human subjects housing these Na v 1.3 mutations display an increased susceptibility to neuropathic pain. Polymorphisms that do not cause overt disease, on the other hand, may be subject to different selective pressures, and it would not be surprising if multiple ion channels were found to house polymorphisms linked to pain. Genes encoding the Na v 1.8 and Na v 1.9 sodium channels, which have strong effects on excitability of nocioceptive dorsal root ganglion neurons (Renganathan et al., 2001; Baker et al., 2003; Rush et al., 2006) , but show limited if any expression in the CNS, would appear to be especially likely to house such polymorphisms. As indicated by K v 9.1, however, ion channel genes that are widely expressed within the brain can also contain polymorphisms that are linked to pain. As additional genetic variants linked to pain are identified, we almost certainly will learn more about the molecular substrates for nocioception and chronic pain, and hopefully will glean information that will bring us closer to more effective treatments for pain.
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